• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [22336 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2011     National Institute for Health and Care Excellence (NICE) Bortezomib and thalidomide for the first-line treatment of multiple myeloma. NICE technology appraisal guidance 228
2020     National Institute for Health and Care Excellence (NICE) Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 649
2023     National Institute for Health and Care Excellence (NICE) Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 911
2006     National Institute for Health and Care Excellence (NICE) Laparoscopic retroperitoneal lymph node dissection for testicular cancer
2011     National Institute for Health and Care Excellence (NICE) Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance 229
2020     National Institute for Health and Care Excellence (NICE) Pembrolizumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 650
2023     National Institute for Health and Care Excellence (NICE) Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease. NICE technology appraisal guidance 912
2006     National Institute for Health and Care Excellence (NICE) Mosaicplasty for knee cartilage defects
2011     National Institute for Health and Care Excellence (NICE) Agomelatine for the treatment of major depressive episodes (terminated appraisal). NICE technology appraisal guidance 231
2020     National Institute for Health and Care Excellence (NICE) Naldemedine for treating opioid-induced constipation. NICE technology appraisal guidance 651
2023     National Institute for Health and Care Excellence (NICE) Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy. NICE technology appraisal guidance 913
2006     National Institute for Health and Care Excellence (NICE) Percutaneous endoscopic colostomy
2011     National Institute for Health and Care Excellence (NICE) Mifamurtide for the treatment of osteosarcoma. NICE technology appraisal guidance 235
2020     National Institute for Health and Care Excellence (NICE) Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 653
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 914
2006     National Institute for Health and Care Excellence (NICE) Photorefractive (laser) surgery for the correction of refractive errors
2011     National Institute for Health and Care Excellence (NICE) Ticagrelor for the treatment of acute coronary syndromes. NICE technology appraisal guidance 236
2020     National Institute for Health and Care Excellence (NICE) Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 654
2023     National Institute for Health and Care Excellence (NICE) Pegunigalsidase alfa for treating Fabry disease. NICE technology appraisal guidance 915
2006     National Institute for Health and Care Excellence (NICE) Stent-graft placement in abdominal aortic aneurysm
2011     National Institute for Health and Care Excellence (NICE) Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. NICE technology appraisal guidance 238
2020     National Institute for Health and Care Excellence (NICE) Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 655
2023     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating active psoriatic arthritis. NICE technology appraisal guidance 916
2006     National Institute for Health and Care Excellence (NICE) Stimulated graciloplasty for faecal incontinence
2011     National Institute for Health and Care Excellence (NICE) Fulvestrant for the treatment of locally advanced or metastatic breast cancer. NICE technology appraisal guidance 239
2020     National Institute for Health and Care Excellence (NICE) Siponimod for treating secondary progressive multiple sclerosis. NICE technology appraisal guidance 656
2023     National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. NICE technology appraisal guidance 917
2011     National Institute for Health and Care Excellence (NICE) Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal). NICE technology appraisal guidance 240
2020     National Institute for Health and Care Excellence (NICE) Carfilzomib for previously treated multiple myeloma. NICE technology appraisal guidance 657
2023     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating axial spondyloarthritis. NICE technology appraisal guidance 918
2012     National Institute for Health and Care Excellence (NICE) Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy. NICE technology appraisal guidance 242
2020     National Institute for Health and Care Excellence (NICE) Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 658
2023     National Institute for Health and Care Excellence (NICE) Rimegepant for treating migraine. NICE technology appraisal guidance 919
2012     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of stage III-IV follicular lymphoma. NICE technology appraisal guidance 243
2020     National Institute for Health and Care Excellence (NICE) Galcanezumab for preventing migraine. NICE technology appraisal guidance 659
2023     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 920
2012     National Institute for Health and Care Excellence (NICE) Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 245
2020     National Institute for Health and Care Excellence (NICE) Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 660
2023     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating polycythaemia vera. NICE technology appraisal guidance 921
2012     National Institute for Health and Care Excellence (NICE) Pharmalgen for the treatment of bee and wasp venom allergy. NICE technology appraisal guidance 246
2020     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. NICE technology appraisal guidance 661
2023     National Institute for Health and Care Excellence (NICE) Daridorexant for treating long-term insomnia. NICE technology appraisal guidance 922
2010     National Institute for Health and Care Excellence (NICE) Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
2012     National Institute for Health and Care Excellence (NICE) Tocilizumab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 247
2020     National Institute for Health and Care Excellence (NICE) Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 662
2023     National Institute for Health and Care Excellence (NICE) Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal). NICE technology appraisal guidance 923
2010     National Institute for Health and Care Excellence (NICE) Prucalopride for the treatment of chronic constipation in women
2012     National Institute for Health and Care Excellence (NICE) Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 254
2020     National Institute for Health and Care Excellence (NICE) Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 663
2023     National Institute for Health and Care Excellence (NICE) Tirzepatide for treating type 2 diabetes. NICE technology appraisal guidance 924
2010     National Institute for Health and Care Excellence (NICE) Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
2010     National Institute for Health and Care Excellence (NICE) SeQuent Please balloon catheter for in-stent coronary restenosis
2012     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE technology appraisal guidance 256
2020     National Institute for Health and Care Excellence (NICE) Liraglutide for managing overweight and obesity. NICE technology appraisal guidance 664
2023     National Institute for Health and Care Excellence (NICE) Mirikizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 925
2010     National Institute for Health and Care Excellence (NICE) Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
2010     National Institute for Health and Care Excellence (NICE) Selective dorsal rhizotomy for spasticity in cerebral palsy
2012     National Institute for Health and Care Excellence (NICE) Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2. NICE technology appraisal guidance 257
2020     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating severe rheumatoid arthritis. NICE technology appraisal guidance 665
2023     National Institute for Health and Care Excellence (NICE) Baricitinib for treating severe alopecia areata. NICE technology appraisal guidance 926
2010     National Institute for Health and Care Excellence (NICE) Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
2010     National Institute for Health and Care Excellence (NICE) Percutaneous radiofrequency ablation for primary or secondary lung cancers
2012     National Institute for Health and Care Excellence (NICE) Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 258
2020     National Institute for Health and Care Excellence (NICE) Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma. NICE technology appraisal guidance 666
2023     National Institute for Health and Care Excellence (NICE) Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 927
2010     National Institute for Health and Care Excellence (NICE) Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
2010     National Institute for Health and Care Excellence (NICE) Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers
2012     National Institute for Health and Care Excellence (NICE) Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. NICE technology appraisal guidance 259
2020     National Institute for Health and Care Excellence (NICE) Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura. NICE technology appraisal guidance 667
2023     National Institute for Health and Care Excellence (NICE) Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine. NICE technology appraisal guidance 928
2010     National Institute for Health and Care Excellence (NICE) Denosumab for the prevention of osteoporotic fractures in postmenopausal women
2010     National Institute for Health and Care Excellence (NICE) Percutaneous closure of patent foramen ovale for recurrent migraine
2012     National Institute for Health and Care Excellence (NICE) Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance 260
2021     National Institute for Health and Care Excellence (NICE) Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer. NICE technology appraisal guidance 668
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 929
2006     National Institute for Health and Care Excellence (NICE) Brief interventions and referral for smoking cessation in primary care and other settings
2010     National Institute for Health and Care Excellence (NICE) Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)
2010     National Institute for Health and Care Excellence (NICE) Low intensity pulsed ultrasound to promote fracture healing
2012     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 261
2021     National Institute for Health and Care Excellence (NICE) Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor. NICE technology appraisal guidance 670
2023     National Institute for Health and Care Excellence (NICE) Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments. NICE technology appraisal guidance 930
2006     National Institute for Health and Care Excellence (NICE) Four commonly used methods to increase physical activity: brief interventions in primary care, exercise referral schemes, pedometers and community-based exercise programmes for walking and cycling
2010     National Institute for Health and Care Excellence (NICE) Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)
2010     National Institute for Health and Care Excellence (NICE) Cryotherapy for the treatment of liver metastases
2012     National Institute for Health and Care Excellence (NICE) Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer. NICE technology appraisal guidance 263
2021     National Institute for Health and Care Excellence (NICE) Mepolizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 671
2023     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 931
2010     National Institute for Health and Care Excellence (NICE) Liraglutide for the treatment of type 2 diabetes mellitus
2010     National Institute for Health and Care Excellence (NICE) Uterine artery embolisation for fibroids
2012     National Institute for Health and Care Excellence (NICE) Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. NICE technology appraisal guidance 265
2021     National Institute for Health and Care Excellence (NICE) Brolucizumab for treating wet age-related macular degeneration. NICE technology appraisal guidance 672
2023     National Institute for Health and Care Excellence (NICE) Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 932
2010     National Institute for Health and Care Excellence (NICE) Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
2010     National Institute for Health and Care Excellence (NICE) Radiation therapy for early Dupuytren's disease
2012     National Institute for Health and Care Excellence (NICE) Mannitol dry powder for inhalation for treating cystic fibrosis. NICE technology appraisal guidance 266
2021     National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 673
2023     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 933
2010     National Institute for Health and Care Excellence (NICE) Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years
2010     National Institute for Health and Care Excellence (NICE) Non-rigid stabilisation techniques for the treatment of low back pain
2012     National Institute for Health and Care Excellence (NICE) Ivabradine for treating chronic heart failure. NICE technology appraisal guidance 267